Fred R. Kohn, PhD
Dr. Kohn is a preclinical development consultant with greater than 25 years of experience in the biotechnology/pharmaceutical industry designing and directing preclinical programs (pharmacology, pharmacokinetics and GLP toxicology) for product development (small molecules, proteins, peptides, monoclonal antibodies, drug delivery systems, cell-based therapies). Dr. Kohn has broad industry experience in companies ranging in size from start-up biotechnology ventures to large pharmaceutical corporations. Dr. Kohn's biomedical areas of expertise include diabetes, autoimmune diseases, inflammation, infectious diseases, pain management and oncology.
Dr. Kohn received a PhD in pharmacology from the University of Minnesota Medical School (1987) and did post-doctoral work in cellular immunology at the BC Cancer Research Centre in Vancouver, British Columbia, Canada. Dr. Kohn has held positions of increasing responsibility at XOMA, DepoTech Corporation, Desmos, Inc., SkyePharma, MicroIslet, Inc. and Pfizer Global R&D. Prior to becoming an independent consultant, Dr. Kohn was Vice President of Preclinical Development at Paramount Biosciences.
Dr. Kohn's areas of expertise include design and implementation of preclinical development plans, management of studies at contract facilities, data interpretation, preparation of regulatory submissions and interaction with regulatory agencies, due diligence of in-licensing candidates, and de-risking strategies for preclinical issues.